Donanemab Clinical Trials

4 actively recruiting trials across 3 locations

▲ +3 trials since June 2026

Also known as: (LY3002813), LY3002813

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

Eli Lilly and Company4

Indications

Alzheimer's Disease4
Alzheimer Disease3
Plaque, Amyloid1
Synucleinopathies1
Amyloid1

Other1 trial

Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

Phase 3

Huntsville, Alabama1 trial

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

Rehabilitation & Neurological Services

Chandler, Arizona1 trial

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

TrialSphere Corp

Phase 2

Phoenix, Arizona1 trial

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

Banner Alzheimer's Institute

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.